EEG / EMG in Delaware

Omniscient Neurotechnology develops AI-powered connectomic analysis software for precision brain mapping and surgical planning. The company specializes in digital brain mapping technology that generates personalized connectomes—computational maps of brain functional and structural connections—using advanced algorithms and cloud-based processing of MRI and resting-state functional MRI (rs-fMRI) data. Quicktome is their flagship platform, an automated connectomic analysis solution designed for neurosurgeons and researchers to extract actionable insights into patient-specific brain networks prior to surgery and for large-scale neural data processing in research settings. The platform supports clinical decision-making across neurologic conditions including cranial surgery, neuro-oncology, depression, Alzheimer's disease, schizophrenia, and stroke. By automating what historically required manual tractography and reducing processing time from hours to under 2 hours with minimal clinician intervention, Quicktome enables faster surgical planning while preserving critical functional brain regions. The company operates through global distribution partnerships and maintains offices in Australia (Sydney, NSW) and the United States (Atlanta). Omniscient holds SOC 2 compliance certification and patents issued by the USPTO. The technology is positioned at the intersection of neuroimaging, artificial intelligence, and cloud computing, serving both clinical and research institutions worldwide.

QuantalX Neuroscience manufactures Delphi-MD™, a non-invasive brain network function assessment device using Direct Electrophysiological Imaging technology to map real-time brain activity. The device captures transcranial magnetic stimulation (TMS)-evoked brain potentials (TEPs) and provides quantitative output parameters compared against a normative reference database for ages 50–75. Unlike conventional neuroimaging, Delphi-MD™ operates in any care setting—clinics, hospitals, research facilities—without radiation exposure. The system is indicated for brain health assessment, neurology, psychiatry, and research applications. FDA De Novo cleared, the device generates comprehensive, age-correlated results reports integrated into clinical workflows. Key features include rapid assessment, radiation-free operation, proven validation through peer-reviewed publications, and cost-effectiveness. Clinical interpretations must be made by qualified healthcare professionals within full patient evaluation context. Potential adverse events include headache, nausea, dizziness, fatigue, insomnia, anxiety, back/neck pain, vomiting, tinnitus, migraine aura, and abnormal sensations. The device is not intended as a sole diagnostic tool. Serves providers, researchers, and institutional buyers seeking objective, accessible brain function measurement.

Vistim Labs develops Ceregram, a patented Evoked Potential Tomography (EPT) technology for non-invasive, radiation-free neurological monitoring. The platform is designed to track disease progression in dementia patients (Alzheimer's, Parkinson's, Lewy Body Disease) and other neurological disorders by localizing and quantifying sensory deficits caused by neurodegeneration. Ceregram monitors across multiple disease endpoints including brain volume changes, physiological markers (amyloid and tau accumulation), and psychological/cognitive performance metrics (MMSE, CERAD, TASIT). The technology enables point-of-care evaluation in office-based clinical settings, allowing physicians to assess treatment response and adjust disease management in real time without requiring PET imaging or other advanced neuroimaging. The company has published peer-reviewed research in Alzheimer's Research and Therapy Journal and presented findings at major conferences including the American Academy of Neurology (2025) and Alzheimer's Association International Conference (2023). Ceregram is positioned as a clinical decision-support tool for cognitive monitoring and is not intended as a diagnostic device or replacement for PET, MRI, or other imaging modalities. The company operates with offices in Miami and San Diego, with affiliate locations in New York, Paris, and Berlin. Vistim Labs has participated in biotech accelerators (PharmStars, Boston) and won multiple startup pitch competitions.